Carolyn F. Deacon
University of Copenhagen
Panum Institute
Department of Biomedical Sciences
DK-2200 Copenhagen N
Denmark
Name/email consistency: high
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Deacon, C.F., Holst, J.J. Expert. Opin. Investig. Drugs (2010)
- Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Deacon, C.F., Holst, J.J. Adv. Ther (2009)
- Immunoassays for the incretin hormones GIP and GLP-1. Deacon, C.F., Holst, J.J. Best Pract. Res. Clin. Endocrinol. Metab. (2009)
- Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Deacon, C.F. Curr. Opin. Investig. Drugs (2008)
- DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Deacon, C.F., Carr, R.D., Holst, J.J. Front. Biosci. (2008)
- Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Deacon, C.F. Diabetes. Obes. Metab (2007)
- Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Deacon, C.F. Expert. Opin. Investig. Drugs (2007)
- Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Deacon, C.F., Holst, J.J. Int. J. Biochem. Cell Biol. (2006)
- GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Deacon, C.F., Plamboeck, A., Rosenkilde, M.M., de Heer, J., Holst, J.J. Am. J. Physiol. Endocrinol. Metab. (2006)
- What do we know about the secretion and degradation of incretin hormones?. Deacon, C.F. Regul. Pept. (2005)
- MK-431 (Merck). Deacon, C.F. Curr. Opin. Investig. Drugs (2005)
- Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. Deacon, C.F., Ahrén, B., Holst, J.J. Expert. Opin. Investig. Drugs (2004)
- Therapeutic strategies based on glucagon-like peptide 1. Deacon, C.F. Diabetes (2004)
- Circulation and degradation of GIP and GLP-1. Deacon, C.F. Horm. Metab. Res. (2004)
- Differential regional metabolism of glucagon in anesthetized pigs. Deacon, C.F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M., Holst, J.J. Am. J. Physiol. Endocrinol. Metab. (2003)
- Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. Deacon, C.F., Wamberg, S., Bie, P., Hughes, T.E., Holst, J.J. J. Endocrinol. (2002)
- GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Deacon, C.F., Plamboeck, A., Møller, S., Holst, J.J. Am. J. Physiol. Endocrinol. Metab. (2002)
- Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Deacon, C.F., Holst, J.J. Biochem. Biophys. Res. Commun. (2002)
- Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Deacon, C.F., Danielsen, P., Klarskov, L., Olesen, M., Holst, J.J. Diabetes (2001)
- Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. Deacon, C.F., Nauck, M.A., Meier, J., Hücking, K., Holst, J.J. J. Clin. Endocrinol. Metab. (2000)
- Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Deacon, C.F., Hughes, T.E., Holst, J.J. Diabetes (1998)
